BILHI Genetics

bilhigenetics.com

Bilhi Genetics is a biotech company at the edge of biotechnology and digital technologies. We ambition to become a major player of the personalized and predictive medicine. We are a start-up benefiting from more than 30 years of research in the field of genomics. More specifically the company aims at bringing new solutions to practitioners involved in curing pathologies causing severe fibrosis evolving into cancers, myocardial infarction, skin scars, kidney failure.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

NORTHWEST BIOTHERAPEUTICS ANNOUNCES THE COMPLETION OF FINANCING ON A FAVORABLE TERMS FOR APPROXIMATELY $8 MILLION

Northwest Biotherapeutics | August 12, 2020

news image

Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a financing on favorable terms for approximately $8 million. The Company anticipates that this financing will help maintain the Company's momentum, and will provide some prudent protection in the midst of the current global economic uncertainties. The financing also further ...

Read More

Medical, Industry Outlook

NONA BIOSCIENCES ANNOUNCES BUSINESS UPDATE OF COLLABORATION ON ANTIBODY DRUG CONJUGATE (ADC) WITH DUALITYBIO

PRNewswire | July 14, 2023

news image

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of integrated solutions from "Idea to IND" (I to ITM) announced that, DualityBio, a collaborator of Nona Biosciences, and BeiGene entered into an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC program for patients with select solid tumors. This program wa...

Read More

Industrial Impact

ETHERNA ANNOUNCES RESEARCH AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY TO ACCESS MRNA TECHNOLOGIES

eTheRNA | February 04, 2022

news image

eTheRNA immunotherapies NV ("eTheRNA") is pleased to announce the start of a strategic partnership with Merck KGaA, Darmstadt, Germany with the signing of a Research Agreement. The partnership will investigate the application of eTheRNA's proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck KGaA, Darmstadt, Germany. The ongoing pandemic has underlined the capability for mRNA vaccines as a new therapeutic modality. eTheRNA an...

Read More

Medical

DOVER TO ACQUIRE MANUFACTURER OF FLOW-MEASUREMENT DEVICES FOR BIOPHARMA AND SEMICONDUCTOR PRODUCTION APPLICATIONS

Dover | May 11, 2022

news image

Dover (NYSE: DOV) announced today that it has entered into a definitive agreement to acquire Malema Engineering Corporation ("Malema"), a designer and manufacturer of high-precision, mission-critical flow-measurement and control instruments serving customers in the biopharmaceutical, semiconductor, and industrial sectors. Malema will become part of the PSG business unit within Dover's Pumps & Process Solutions segment. Malema's products will expand Dover'...

Read More
news image

NORTHWEST BIOTHERAPEUTICS ANNOUNCES THE COMPLETION OF FINANCING ON A FAVORABLE TERMS FOR APPROXIMATELY $8 MILLION

Northwest Biotherapeutics | August 12, 2020

Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a financing on favorable terms for approximately $8 million. The Company anticipates that this financing will help maintain the Company's momentum, and will provide some prudent protection in the midst of the current global economic uncertainties. The financing also further ...

Read More
news image

Medical, Industry Outlook

NONA BIOSCIENCES ANNOUNCES BUSINESS UPDATE OF COLLABORATION ON ANTIBODY DRUG CONJUGATE (ADC) WITH DUALITYBIO

PRNewswire | July 14, 2023

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of integrated solutions from "Idea to IND" (I to ITM) announced that, DualityBio, a collaborator of Nona Biosciences, and BeiGene entered into an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC program for patients with select solid tumors. This program wa...

Read More
news image

Industrial Impact

ETHERNA ANNOUNCES RESEARCH AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY TO ACCESS MRNA TECHNOLOGIES

eTheRNA | February 04, 2022

eTheRNA immunotherapies NV ("eTheRNA") is pleased to announce the start of a strategic partnership with Merck KGaA, Darmstadt, Germany with the signing of a Research Agreement. The partnership will investigate the application of eTheRNA's proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck KGaA, Darmstadt, Germany. The ongoing pandemic has underlined the capability for mRNA vaccines as a new therapeutic modality. eTheRNA an...

Read More
news image

Medical

DOVER TO ACQUIRE MANUFACTURER OF FLOW-MEASUREMENT DEVICES FOR BIOPHARMA AND SEMICONDUCTOR PRODUCTION APPLICATIONS

Dover | May 11, 2022

Dover (NYSE: DOV) announced today that it has entered into a definitive agreement to acquire Malema Engineering Corporation ("Malema"), a designer and manufacturer of high-precision, mission-critical flow-measurement and control instruments serving customers in the biopharmaceutical, semiconductor, and industrial sectors. Malema will become part of the PSG business unit within Dover's Pumps & Process Solutions segment. Malema's products will expand Dover'...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us